CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for King Pharmaceuticals LLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

King Pharmaceuticals LLC
501 Fifth Street
Phone: (423) 989-8000p:423 989-8000 Bristol, TN  37620  United States Fax: (423) 274-8677f:423 274-8677
This company was Merged or Acquired on 3/1/2011.
This company ceased filing statements with the SEC on 3/1/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
King Pharmaceuticals LLC (King) is engaged in the pharmaceutical industry. The company performs basic research and develops, manufactures, markets and sells branded prescription pharmaceutical products and animal health products. Some of its branded prescription pharmaceuticals include neuroscience products such as Skelaxin, Flector Patch, Avinza and Embeda; hospital products such as Thrombin-JMI; and legacy products such as Levoxyl, Bicillin, Altace and Cytomel. The animal health business focuses on medicated feed additives and water-soluble therapeutics. The Company also manufactures and markets pharmaceutical products, one in which that is delivered using an EpiPen.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201012/31/2009YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Business Names
Business Name
Alpha-Lux Investments S.àr.l.
Alpharma (Bermuda) G.P.
Alpharma (Luxembourg) S.àr.l.
5 additional Business Names available in full report.

General Information
Outstanding Shares: 249,968,580 (As of 11/2/2010)
Shareholders: 795
Stock Exchange: NYSE
Federal Tax Id: 541684963
Fax Number: (423) 274-8677


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023